Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Lovejoy

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bulletin of the History of Medicine|January 1, 1975
The Osler medal essay: The hospital and society: the growth of hospitals in Rochester, New York, in the nineteenth centuryD B Lovejoy
Current Medicinal Chemistry|April 8, 2003
Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelatorsD B Lovejoy, D R Richardson
Expert Opinion on Investigational Drugs|November 4, 2000
Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasiaD R Richardson, D B Lovejoy
Acta Crystallographica. Section C, Crystal Structure Communications|April 25, 2000
2-hydroxy-1-naphthaldehyde 2-methylthiosemicarbazoneD B Lovejoy, D R Richardson, P V Bernhardt
SLAS Discovery : Advancing Life Sciences R & D|February 9, 2018
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor ScaffoldsK R Jacobs, G J Guillemin, D B Lovejoy
Biochimica Et Biophysica Acta|May 20, 2008
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agentsD R Richardson, D S Kalinowski, S Lau, et al.
Current Drug Delivery|May 29, 2010
Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour ActivityZ Kovacevic, D S Kalinowski, D B Lovejoy, et al.
British Journal of Cancer|January 8, 2009
ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cellsA Bohlken, B B Cheung, J L Bell, et al.
British Journal of Pharmacology|November 7, 2012
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivoS J Ford, P Obeidy, D B Lovejoy, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bulletin of the History of Medicine|January 1, 1975
The Osler medal essay: The hospital and society: the growth of hospitals in Rochester, New York, in the nineteenth centuryD B Lovejoy
Current Medicinal Chemistry|April 8, 2003
Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelatorsD B Lovejoy, D R Richardson
Expert Opinion on Investigational Drugs|November 4, 2000
Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasiaD R Richardson, D B Lovejoy
Acta Crystallographica. Section C, Crystal Structure Communications|April 25, 2000
2-hydroxy-1-naphthaldehyde 2-methylthiosemicarbazoneD B Lovejoy, D R Richardson, P V Bernhardt
SLAS Discovery : Advancing Life Sciences R & D|February 9, 2018
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor ScaffoldsK R Jacobs, G J Guillemin, D B Lovejoy
Biochimica Et Biophysica Acta|May 20, 2008
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agentsD R Richardson, D S Kalinowski, S Lau, et al.
Current Drug Delivery|May 29, 2010
Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour ActivityZ Kovacevic, D S Kalinowski, D B Lovejoy, et al.
British Journal of Cancer|January 8, 2009
ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cellsA Bohlken, B B Cheung, J L Bell, et al.
British Journal of Pharmacology|November 7, 2012
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivoS J Ford, P Obeidy, D B Lovejoy, et al.
Pageof 1